JAC Advance Access originally published online on July 28, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy 2004 54(3):648-653; doi:10.1093/jac/dkh387
JAC vol.54 no.3 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved.
Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model
1 Department of Medical Microbiology, Dermatology and Infection, Lund University, Sölvegatan 23, SE-223 62 Lund, Sweden; 2 Institute for Medical Microbiology and Immunology, University of Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany
* Corresponding author. Tel: +46-46-177066; Fax: +46-46-189117; Email: danuta.kruszewska{at}telia.com
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) often colonize the anterior nares, and nasal carriage remains the main source of bacterial dissemination. The aim of this study was to assess the in vivo activity of the lantibiotic mersacidin against MRSA colonizing nasal epithelia.
Methods: The efficiency of mersacidin in the eradication of MRSA was tested employing mice pre-treated with hydrocortisone and inoculated intranasally either three or six times with a bacterial suspension.
Results: In mersacidin-treated animals, pre-colonized with MRSA, bacteria could not be detected in blood, lungs, liver, kidney, spleen or nasal scrapings and there were no lesions manifested after intraperitoneal drug application. Blood samples from infected mice obtained 2 h after mersacidin therapy revealed anti-MRSA activity in a serum bactericidal test. Moreover, elevated interleukin-1ß and tumour necrosis factor-
titres were noticed in the pre-infected but not in cured animals. In contrast, mersacidin did not induce differences in the cytokine profiles of treated uninfected control mice.
Conclusions: In the mouse rhinitis model, mersacidin was able to eradicate MRSA colonization. The site of action (epithelium versus blood) of mersacidin needs to be further explored.
Keywords: lantibiotics , mouse model , MRSA nasal carriage
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Begley, P. D. Cotter, C. Hill, and R. P. Ross Identification of a Novel Two-Peptide Lantibiotic, Lichenicidin, following Rational Genome Mining for LanM Proteins Appl. Envir. Microbiol., September 1, 2009; 75(17): 5451 - 5460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. de Kwaadsteniet, K. ten Doeschate, and L. M. T. Dicks Characterization of the Structural Gene Encoding Nisin F, a New Lantibiotic Produced by a Lactococcus lactis subsp. lactis Isolate from Freshwater Catfish (Clarias gariepinus) Appl. Envir. Microbiol., January 15, 2008; 74(2): 547 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Valsesia, G. Medaglia, M. Held, W. Minas, and S. Panke Circumventing the Effect of Product Toxicity: Development of a Novel Two-Stage Production Process for the Lantibiotic Gallidermin Appl. Envir. Microbiol., March 1, 2007; 73(5): 1635 - 1645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Jenssen, P. Hamill, and R. E. W. Hancock Peptide Antimicrobial Agents Clin. Microbiol. Rev., July 1, 2006; 19(3): 491 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Cotter, L. A. Draper, E. M. Lawton, O. McAuliffe, C. Hill, and R. P. Ross Overproduction of wild-type and bioengineered derivatives of the lantibiotic lacticin 3147. Appl. Envir. Microbiol., June 1, 2006; 72(6): 4492 - 4496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Schaffer, R. M. Solinga, J. Cocchiaro, M. Portoles, K. B. Kiser, A. Risley, S. M. Randall, V. Valtulina, P. Speziale, E. Walsh, et al. Immunization with Staphylococcus aureus Clumping Factor B, a Major Determinant in Nasal Carriage, Reduces Nasal Colonization in a Murine Model Infect. Immun., April 1, 2006; 74(4): 2145 - 2153. [Abstract] [Full Text] [PDF]
|
|